Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara

Journal of Virology

Volumn 70, Issue 6, 1996, Pages 3741-3752

  Hirsch, Vanessa M ^a,g   Fuerst, Thomas R ^b   Sutter, Gerd ^a   Carroll, Miles W ^a   Yang, Limei C ^c   Goldstein, Simoy ^a   Piatak Jr , Michael ^c   Elkins, William R ^a   Gregory Alvord, W ^d   Montefiori, David C ^e,f   Moss, Bernard ^a   Lifson, Jeffrey D ^d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Becton Dickinson Diagn Instrum S ^*  (United States)

^c BD Technologies   (United States)

^d SAIC FREDERICK INC   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f DUKE UNIVERSITY   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TRIPLE VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ARTICLE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INTRAMUSCULAR DRUG ADMINISTRATION; MACACA; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; VIREMIA; VIRUS REPLICATION;

ANIMALS; BASE SEQUENCE; GENES, ENV; GENES, GAG; GENES, POL; IMMUNIZATION; LYMPH NODES; MACACA MULATTA; MOLECULAR SEQUENCE DATA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 0029940996     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Arthur, L. O., J. W. Bess, R. C. Sowder, R. E. Benveniste, D. L. Mann, J.-C. Chermann, and L. E. Henderson. 1992. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 258:1935-1938.
2. Baskin, G., L. N. Martin, M. Murphey-Corb, F.-S. Hu, D. Kuebler, and B. Davison. 1995. Distribution of SIV in lymph nodes of serially sacrificed rhesus monkeys. AIDS Res. Hum. Retroviruses 11:273-285.
3. Baskin, G. B., M. Murphey-Corb, E. A. Watson, and L. N. Martin. 1989. Necropsy findings in rhesus monkeys experimentally infected with cultured simian immunodeficiency virus (SIV/Delta). Vet. Pathol. 25:456-467.
4. Biberfeld, P., K. J. Chayt, L. M. Marselle, G. Biberfeld, R. C. Gallo, and M. Harper. 1986. HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. Am. J. Pathol. 123:436-440.
5. Buller, R. M. L., G. L. Smith, K. Cremer, A. L. Notkins, and B. Moss. 1985. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase negative phenotype. Nature (London) 317:813-815.
6. Cao, Y., L. Qin, L. Zhang, J. Safrit, and D. Ho. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:201-208.
7. 6a.Carroll, M. W., W. W. Overwijk, R. Chamberlain, S. A. Rosenberg, B. Moss, and N. P. Restifo. Unpublished data.
8. Chakrabarti, L., M.-C. Cumont, L. Montagnier, and B. Hurtrel. 1994. Variable course of simian immunodeficiency virus infection in lymph nodes: relation to disease progression. J. Virol. 68:6634-6642.
9. 7a.Chakrabarti, S., and B. Moss. Unpublished data.
10. + T cells. Science 270:1811-1815.
11. Cochran, M. A., C. Puckett, and B. Moss. 1985. In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory synthesis. J. Virol. 54:30-37.
12. Codoz, M., A. Stradt, B. Meignier, J. Taylor, J. Tartaglia, E. Paoletti, and S. Plotkin. 1992. Immunization with canarypox expressing rabies glycoprotein. Lancet iii:1529-1532.
13. Cranage, M. P., N. Polyanskaya, B. McBride, N. Cook, L. A. E. Ashworth, M. Dennis, A. Baskerville, P. J. Greenway, T. Corcoran, P. Kitchin, J. Rose, M. Murphey-Corb, R. C. Desroisiers, E. J. Stott, and G. H. Farrar. 1993. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res. Hum. Retroviruses 9:13-22.
14. Crowder, M. J., and D. J. Hand. 1990. Analyses of repeated measures. Chapman & Hall, New York.
15. Daniel, M. D., F. Kirchoff, S. C. Czajak, P. K. Seghal, and R. C. Desrosiers. 1992. Protective effects of live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938-1941.
16. Embertson, J., M. Zupancic, J. L. Ribas, A. Burke, P. Racz, K. Tenner-Racz, and A. Haase. 1994. Massive covert infection of helper T lymphocytes by HIV during the incubation period of AIDS. Nature (London) 362:359-362.
17. Fox, C., C. Tenner-Racz, P. Racz, A. Firpo, P. A. Pizzo, and A. S. Fauci. 1991. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J. Infect. Dis. 164:1051.
18. Galasso, G. D., D. T. Karzon, S. L. Katz, S. Krugman, J. Neff, and F. C. Robbins. 1977. Smallpox vaccines comparing variations in dose and route of administration. J. Infect. Dis. 135:131-186.
19. Giavedoni, L. D., V. Planelles, N. L. Haigwood, S. Ahmad, J. D. Kluge, M. L. Marthas, M. B. Gardner, P. A. Luciw, and T. D. Yilma. 1993. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J. Virol. 67:577-583.
20. Goldstein, S., W. R. Elkins, W. T. London, A. Hahn, R. Goeken, J. E. Martin, and V. M. Hirsch. 1994. Immunization with whole inactivated vaccine pro-tects from infection by SIV grown in human hut not macaque cells. J. Med. Primatol. 23:75-82.
21. Guo, S., R. Simon, J. E. Talmadge, and J. E. Klabansky. 1987. An interactive computer program for the analysis of growth curves. Comput. Biomed. Res. 20:37-48.
22. Haigwood, N., A. Watson, J. McClure. W. F. Sutton, J. Ranchalis, B. Travis, S.-L. Hu, V. M. Hirsch, G. Voss, N. Letvin, A. Lewis, and P. R. Johnson. 1995. Passive immune globulin therapy in the SIV/macaque model reduces viremia and delays disease, p. 149-158. In R. Chanock, F. Brown, H. Ginsberg, and E. Norby (ed.), Vaccines 95. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
23. Hirsch, V., S. Goldstein, R. Chanock, W. R. Elkins, G. Sutter, B. Moss, J. Sisler, J. Lifson, and T. Fuerst. 1995. Limited virus replication following SIV challenge of macaques immunized with attenuated MVA vaccinia expressing SIVsm env and gag-pol, p. 195-200. In R. Chanock, F. Brown, H. Ginsberg, and E. Norby (ed.), Vaccines 95. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. N.Y.
24. 21a.Hirsch, V. M. Unpublished data.
25. Hirsch, V. M., G. Dapolito, P. R. Johnson, W. R. Elkins, W. T. London, R. J. Montali, S. Goldstein, and C. Brown. 1995. Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with extent of in vivo replication. J. Virol. 69:955-967.
26. Hirsch, V. M., S. Goldstein, N. A. Hynes, W. R. Elkins, W. T. London, P. M. Zack, D. Montefiori, and P. R. Johnson. 1994. Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. J. Infect. Dis. 170:51-59.
27. Hirsch, V. M., and P. R. Johnson. 1994. Pathogenic diversity of simian immunodeficiency viruses. Virus Res. 32:183-203.
28. Ho, D., A. V. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 373:123-126.
29. Hu, S.-L., K. Abrams, G. Barber, P. Moran, J. M. Zarling, A. J. Langlois, L. Kuller, W. R. Morton, and R. E. Benveniste. 1992. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456-459.
30. Israel, Z. R., P. F. Edmondson, D. H. Maul, S. P. O'Neil, S. P. Mossman, C. Thiriart, L. Fabry, O. Van Opstal, C. Bruck, F. Bex, A. Burny, P. N. Fultz, J. I. Mullins, and E. A. Hoover. 1994. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J. Virol. 68:1843-1853.
31. Johnson, P. R., D. C. Montefiori, S. Goldstein, et al. 1992. Inactivated whole-virus vaccine derived from a proviral molecular clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. Proc. Natl. Acad. Sci. USA 89:2175-2179.
32. Kalbfleish, J. D., and R. L. Prentice. 1980. The statistical analysis of failure time data. John Wiley & Sons, Inc., New York.
33. Kirchoff, F., T. C. Greenough, D. B. Brettler, J. L. Sullivan, and R. C. Desrosiers. 1995. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Engl. J. Med. 332:228-232.
34. Koziol, J. A., and D. A. Maxwell. 1981. A distribution-free test for tumor growth analyses with application to an animal tumor immunotherapy experiment. Biometrics 37:383-390.
35. Lohman, B., M. McChesney, C. J. Miller, E. McGowan, S. M. Joye, K. K. A. Van Rompey, E. Reay, L. Antipa, N. C. Pederson, and M. L. Marthas. 1994. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J. Virol. 68: 7021-7029.
36. Mackett, M., G. L. Smith, and B. Moss. 1984. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 49:857-864.
37. Marthas, M., S. Sujipto, J. Higgins, B. Lohman, J. Torten, P. A. Luciw, P. A. Marx, and N. C. Pedersen. 1990. Immunization with a live attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. j. Virol. 64:3694-3700.
38. Mayr, A., V. Hochstein, and H. Stickl. 1975. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-stammes MVA. Infection 3:6-14.
39. McClure, H. M., D. C. Anderson, P. N. Fultz, A. A. Ansari, E. Lockwood, and A. Brodie. 1989. Spectrum of disease in macaques monkeys chronically infected with SIVsmm. Vet. Immunol. Immunopathol. 21:13-24.
40. Meyer, H., G. Sutter, and A. Mayr. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1031-1038.
41. Michael, N., M. Vahey, D. S. Burke, and R. R. Redfield. 1992. Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease. J. Virol. 66:310-316.
42. Montenori, D. C., W. E. Robinson, S. S. Schuffman, and W. M. Mitchell. 1988. Evaluation of antiviral drugs and neutralizing antibodies against human immunodeficiency virus by a rapid and sensitive microtiter assay. J. Clin. Microbiol. 26:231-235.
43. Morrison, D. F. 1976. Multivariate statistical methods, 2nd ed. McGraw-Hill, New York.
44. Panteleo, G., C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (London) 362:355-358.
45. Panteleo, G., S. Menzo, M. Vaccarezza, C. Graziosi, O. J. Cohen, J. F. Demarest, D. Montefiori, J. M. Orenstein, C. Fox, L. K. Schrager, J. B. Margolick, S. Buchbinder, J. V. Giorgi, and A. S. Fauci. 1995. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332:209-216.
46. Piatak, M., K.-C. Luk, B. Williams, and J. D. Lifson. 1993. Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. BioTechniques 14:70-77.
47. Piatak, M., M. S. Saag, L. C. Yang, S. J. Clark, J. C. Kappes, K. C. Luk, B. H. Hahn, G. M. Shaw, and J. D. Lifson. 1993. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-1754.
48. Putkonen, P., L. Walther, Y.-J. Zhang, S.-L. Li, C. Nilsson, J. Albert, P. Biberfeld, R. Thorensson, and G. Biberfeld. 1995. Longterm protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine. Nature Med. 1:914-918.
49. Reimann, K., K. Tenner-Racz, P. Racz, D. Montefiori, Y. Yasutomi, W. Lin, B. J. Ransil, and N. L. Letvin. 1994. Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J. Virol. 68:2368-2370.
50. Smith, G. L. 1994. Virus strategies for evasion of the host response to infection. Trends Microbiol. 2:81-88.
51. Sutter, G., and B. Moss. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89:10847-10851.
52. Sutter, G., L. S. Wyatt, P. L. Foley, J. R. Bennick, and B. Moss. 1994 A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12:53-59.
53. Tartaglia, J., M. E. Perkus, J. Taylor, E. K. Norton, J. C. Audonnet, W. I. Cox, S. W. Davis, J. Vanderhoeven, B. Meigner, M. Riviere, B. Languet, and E. Paoletti. 1992. NYVAC - a highly attenuated strain of vaccinia virus. Virology 188:217-232.
54. Tenner-Racz, K., P. Racz, S. Gardner, et al. 1988. Ultrastructural analysis of germinal centers in lymph nodes of patients with HIV-1-induced persistent generalized lymphadenopathy: evidence for persistence of infection. Prog. AIDS Pathol. 1:29-40.
55. + cells involves a noncytotoxic mechanism. J. Virol. 65:5921-5927.
56. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowalk, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 373:117.
57. Winer, B. J., D. R. Brown, and D. Michels. 1991. Statistical principles in experimental design, 2nd ed. McGraw-Hill, New York.